Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma - Heilgeist - 2012 -...
Among 144 patients with MZL, 96 patients (67%) had extralymph node (extranodal) MZL, 32 patients (22%) had lymph node (nodal) MZL, and 16 patients (11%) had splenic MZL. The 5-year progression-free survival rate was 82% in the nodal MZL group, 88% in the extranodal MZL group, and 74% in the splenic MZL group and did not different between the 3 groups (P = .60). The 5-year overall survival rate was excellent in all 3 MZL groups (nodal MZL, 89%; extranodal MZL, 92%; splenic MZL, 82%; P = .46). In our cohort, the FLIPI score was a significant prognostic marker: The 5-year progression-free survival rate for patients who had FLIPI scores of 0 to 2 (low or intermediate risk) was excellent at 92%, whereas it was only 62% for patients who had FLIPI scores of 3 to 5 (poor risk; P = .003). Similarly, the 5-year overall survival rate for patients who had FLIPI scores of 0 to 2 was 95%, whereas it was only 62% for patients who had FLIPI scores of 3 to 5 (P = .0009). ...http://www.onlinelibrary.wiley.com/doi/10.1002/cncr.27704/abstract
Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma - Heilgeist - 2012 -...
MZL is a rare type of malignant B-cell lymphoma. Because of the paucity of large clinical trials, the standard treatment for MZL is still a matter of debate. The purpose of this study was to analyze the role of prognostic markers, treatments, and outcomes in a large cohort of 144 patients with MZL who were diagnosed at our institution between 2003 and 2010. Most of our patients (67%) were diagnosed with extranodal MZL, whereas splenic MZL (11%) was the rarest type. Patient with localized disease received radiotherapy and achieved high response rates (CR, 76%). Like in other indolent lymphomas,19 rituximab has demonstrated effectiveness in the treatment of MZL.20-22 However, a prospective randomized trial on this issue is still missing. In our cohort, among those who chose systemic therapy, 79% of patients with nodal MZL and 87% of patients with extranodal MZL received rituximab with or without chemotherapy. ...http://www.onlinelibrary.wiley.com/doi/10.1002/cncr.27704/full
Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance:...
We assessed the efficacy of fludarabine, cyclophosphamide, and rituximab in combination (FCR) as frontline treatment in patients with follicular lymphoma (FL) followed by rituximab maintenance. Seventy-five untreated patients with FL received FCR followed by maintenance with rituximab 375 mg/m(2) weekly during 4 weeks and every 6 months for 2 years. The overall response rate was 100%, with 89% complete remission (CR) and 11% partial remission (PR). Molecular remission was observed in all but one patient. Only eight patients completed all therapy planned. With a median follow-up of 47 months, the 5-year overall survival (OS), progression-free survival (PFS), and event-free survival (EFS) were 77%, 93%, and 72%, respectively. Age below 60 and low Follicular Lymphoma International Prognostic Index (FLIPI) correlated with a better EFS. Ten patients died due to toxic complications. The FCR regimen is highly ...http://www.mdanderson.es/en/publications/frontline-treatment-follicular-lymphoma-fludarabine-cyclophosphamide-and-rituximab-foll
Proteomic analysis identifies differential expression patterns in follicular lymphoma patients with or without subsequent...
Proteomic analysis identifies differential expression patterns in follicular lymphoma patients with or without subsequent histological ...http://www.forskningsdatabasen.dk/catalog/2185900748
Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma - Full Text View -...
RATIONALE: Monoclonal antibodies, such as epratuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving epratuzumab and rituximab together may be more effective in treating follicular non-Hodgkin lymphoma.. PURPOSE: This phase II trial is studying how well giving epratuzumab together with rituximab works in treating patients with previously untreated follicular non-Hodgkin lymphoma. ...https://clinicaltrials.gov/ct2/show/study/NCT00553501?show_locs=Y
Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma
All information about the latest scientific publications of the Clínica Universidad de Navarra. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphomahttp://www.cun.es/en/research/scientific-publications/role-of-anti-idiotype-vaccines-in-the-modern-treatment-of-human-follicular-lymphoma
Idiotypic Vaccination for Follicular Lymphoma Patients - Full Text View - ClinicalTrials.gov
Idiotypic vaccination has already proved capable (in responding patients) of: biological efficacy, that is the capacity of inducing an idiotype- and tumor-specific immune response (Kwak LW et al. NEJM 1992); clinical efficacy, that is the capacity of inducing specific immune responses able to kill in vivo follicular lymphoma cells that had survived pre-vaccine chemotherapy (Bendandi M et al. Nature Med 1999): clinical benefit, that is the capacity of prolonging survival of responding patients (Inoges et al. JNCI 2006). Now, we want to test whether it is also capable of contributing to the ultimate goal of preventing relapse indefinitely in responding patients ...https://clinicaltrials.gov/ct2/show/NCT00530140
Longer Survival Observed With CHVP Plus Interferon in Elderly High-Risk Follicular Lymphoma Patients | Cancer Network | The...
LYON, France-The addition of interferon-alfa-2b (IFN, Intron A) to the usual CHVP regimen (cyclophosphamide, doxorubicin, teniposide, prednisone) extends survival in elderly patients with high-risk follicular lymphoma, Dr. Bertrand Coiffier said at the ASH meeting. 1http://www.cancernetwork.com/articles/longer-survival-observed-chvp-plus-interferon-elderly-high-risk-follicular-lymphoma-patients
Roche - FDA approves Roche's Gazyva for previously untreated advanced follicular lymphoma
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The approval is based on results from the phase III GALLIUM study, which showed superior progression-free survival (PFS) for patients who received this Gazyva-based regimen compared with those who received a Rituxan® (rituximab)-based regimen as an initial (first-line) therapy. Follicular lymphoma, the most common slow-growing (indolent) form of non-Hodgkin lymphoma (NHL), is incurable and becomes harder to treat each time it returns.. "Today's Gazyva approval is an important advance for the thousands of people diagnosed each year with follicular lymphoma who hope to delay ...https://www.roche.com/de/investors/updates/inv-update-2017-11-17.htm
Follicular lymphoma symptoms, treatments & patient forums | PatientsLikeMe
Follicular lymphoma: Find the most comprehensive real-world symptom and treatment data on follicular lymphoma at PatientsLikeMe. 133 patients with follicular lymphoma experience Insomnia, Anxious mood, Fatigue, Pain, and Depressed mood and use Rituximab, Radiation Therapy, Bendamustine, R-CHOP protocol, and Acetaminophen-Diphenhydramine to treat their follicular lymphoma and its symptoms.https://www.patientslikeme.com/conditions/244-follicular-lymphoma
First-line Treatment Strategies for Advanced-Stage Follicular Lymphoma: Which is The Best One? | ESMO
The Young Oncologists Journal Club, an initiative from the European Society from Medical Oncology. Read the latest article on gastrointestinal cancer.http://esmo.org/Career-Development/Young-Oncologists-Corner/Journal-Club/First-line-Treatment-Strategies-for-Advanced-Stage-Follicular-Lymphoma-Which-is-The-Best-One
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic...
PRIMARY OBJECTIVES:. I. To evaluate the safety of Pegfilgrastim in combination with rituximab in patients with untreated or relapsed/refractory follicular, SLL or MZL.. SECONDARY OBJECTIVES:. I. To evaluate the efficacy (including overall response rate and durability of objective responses) of Pegfilgrastim in combination with rituximab in patients with untreated or relapsed/refractory follicular, SLL or MZL.. II. To evaluate functional and phenotypic characteristics of host neutrophils undergoing treatment with Pegfilgrastim and rituximab.. III. To evaluate changes in cluster of differentiation (CD)20 antigen expression and density of expression in patients receiving Pegfilgrastim and rituximab.. IV. To evaluate changes in serum levels of tumor necrosis factor (TNF), interferon alpha (INFalpha) and free radical levels in patients undergoing treatment with Pegfilgrastim and rituximab.. OUTLINE:. Patients receive pegfilgrastim subcutaneously (SC) followed by rituximab intravenously (IV) 3 days ...https://clinicaltrials.gov/ct2/show/record/NCT00524628
Primary cutaneous follicle center lymphoma with diffuse CD30 expression: a report of 4 cases of a rare variant - Zurich Open...
TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents ...http://www.zora.uzh.ch/id/eprint/99609/
FDA Gives Copanlisib Priority Review for Treating Follicular Lymphoma
The FDA granted priority review status to the new drug application of copanlisib for the treatment of refractory or relapsed follicular lymphoma patients.https://lymphomanewstoday.com/2017/05/18/fda-copanlisib-priority-review-follicular-lymphoma/
Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. - Canada's Michael Smith Genome...
Follicular lymphoma (FL) is an indolent, yet incurable B cell malignancy. A subset of patients experience an increased mortality rate driven by two distinct clinical end points: histological transformation and early progression after immunochemotherapy. The nature of tumor clonal dynamics leading to these clinical end points is poorly understood, and previously determined genetic alterations do not explain the majority of transformed cases or accurately predict early progressive disease. We contend that detailed knowledge of the expansion patterns of specific cell populations plus their associated mutations would provide insight into therapeutic strategies and disease biology over the time course of FL clinical histories.http://www.bcgsc.ca/platform/publications/histological-transformation-and-progression-in-follicular-lymphoma-a-clonal-evolution-study/view
What is Follicular Lymphoma?
Follicular lymphoma is a cancer of the B-cells that accounts for around one third of all cases of lymphoma. The cancer is a form of non-Hodgkin lymphoma that usually affects adults, with an average age-at-diagnosis of 60. Follicular lymphoma is more common among women than among men.https://www.news-medical.net/health/What-is-Follicular-Lymphoma.aspx
Initial treatment of limited stage (I/II) follicular lymphoma
Follicular lymphoma (FL, previously called follicle center lymphoma) is the second most common type of non-Hodgkin lymphoma (NHL). It is the most common of the indolent NHLs defined as those lymphomas in which survival of the untreated patient is meahttps://www.uptodate.com/contents/initial-treatment-of-limited-stage-i-ii-follicular-lymphoma
NCCN Guidelines for Patients® | Follicular Lymphoma Grade 1-2
15 NCCN Guidelines for Patients ® : Follicular Lymphoma, Grade 1-2, 2017 2 Treatment planning 16 Medical history 17 Physical exam 17 Blood tests 19 Imaging tests 20 Bone marrow exam 21 Heart tests 21 Fertility and pregnancy 22 Review ...https://www.nccn.org/patients/guidelines/nhl-follicular_lymphoma/17/
Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma - UNM Comprehensive Cancer Center
Treatment including the targeted agent Gazyva (obinutuzumab) delays cancer progression for a longer period of time than treatment with Rituxan (rituximab) among patients with follicular lymphoma who have not received prior therapy. These results were recently presented at a plenary session of the 2016 annual meeting of the American Society of Hematology (ASH).. Follicular lymphoma (FL) is a type of lymphoma, or cancer that starts in immune cells called B-cells. FL is often considered a slow-growing type of cancer, but in its advanced stages, can become more aggressive.. B-cells have molecules on their surface called CD-20 antigens. Since B-cells turn cancerous in FL, agents targeted against the CD-20 antigens promote the immune system to specifically kill the cancer cells, without harming healthy cells in ...http://cancer.unm.edu/2016/12/15/gazyva-improves-outcomes-compared-to-rituxan-in-untreated-follicular-lymphoma/
New information I received this morning... | Cancer Survivors Network
I just received this up-date in my e-mail this morning, so I thought I'd share it with you. Hope everyone has a "great" day!...Love...Sue (FNHL-2-3A-6/10) age 61. FDA Approves Removal of Bioscan Requirement for Ibritumomab Tiuxetan (Zevalin) On November 18, 2011, the U.S. Food and Drug Administration (FDA) removed the pre-treatment bioscan requirement, which changed the existing treatment regimen for ibritumomab tiuxetan (Zevalin). Zevalin is a form of radioimmunotherapy, a cancer therapy that combines a monoclonal antibody with a radioisotope, a source of radiation. Zevalin was first approved by the FDA in February 2002 for the treatment of patients with relapsed or refractory, low-grade, or follicular lymphoma. In September 2009, the FDA also approved Zevalin for previously untreated follicular lymphoma patients who achieved a partial or complete response to first-line chemotherapy. The removal of the bioscan as part of the treatment ...https://csn.cancer.org/node/231437
Palatal Swelling As The First And Only Manifestation Of Extranodal Follicular Non-Hodgkin Lymphoma: A Case Presentation
Non-Hodgkin lymphomas (NHLs) in the head and neck region are malignant lymphoid neoplasms that usually originate from B-lymphocytic cell lines. Primary extranodal manifestations of this hematolymphoid tumor in the oral cavity are rare and involve the maxillary jaw including the palatal soft tissues, the mandible, and gingival tissues in patients between 60 and 70 years of age without sex predilection. This case report of an extra nodal NHL in the palate of a 75-year-old patient emphasizes the importance of accurate clinical, radiographic, and histologic diagnostic procedures to avoid delayed diagnosis or inappropriate treatment strategies. Chemotherapy, radiotherapy, or a combination of the two with a regular clinical and hemic follow-up is recommended. (Quintessence Int 2010;41:93 97 ...http://www.quintpub.com/journals/qi/abstract.php?iss2_id=609&article_id=7317&article=2&title=Palatal%20Swelling%20As%20The%20First%20And%20Only%20Manifestation%20Of%20Extranodal%20Follicular%20Non-Hodgkin%20Lymphoma:%20A%20Case%20Presentation
Histologic transformation of follicular lymphoma
Follicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma (NHL). It is the most common of the clinically indolent NHLs defined as those lymphomas in which survival of the untreated patient is measured in years. Histologic transfhttp://www.uptodate.com/contents/histologic-transformation-of-follicular-lymphoma
Vascular patterns in reactive lymphoid tissue and in non-Hodgkin's lymphoma. - Nuffield Department of Orthopaedics,...
The few studies published on angiogenesis in lymphoma have raised the question of whether or not microvessel density (MVD) is associated with more aggressive disease and have reported the observation that in follicular lymphomas, vessels are mature rather than immature. We investigated MVD and the vascular phenotype within follicular or diffuse large B-cell lymphomas, reactive nodes and tonsils. Vascular phenotype was defined by the expression or loss of reactivity to the antibody LH39 (detecting the LH39 laminin epitope of the basement membrane in mature vessels) and by detection of alpha V beta 3 (expressed on immature vessels). In reactive nodes and in follicular lymphomas, MVD was higher in the paracortex than in germinal centres or in neoplastic follicles. However, in neoplastic follicles an increase in alpha V beta 3-positive endothelium suggested the ...https://www.ndorms.ox.ac.uk/publications/124902
Transplants no benefit in advanced follicular lymphoma
Results of a systematic review and meta-analysis of randomized control trials ranging from 1947 through 2009 showed researchers that high-dose chemotherapy followed by stem cell transplantation did not improve overall survival in patients with advanced, treatment naive follicular lymphoma compared to chemotherapy alone.http://www.lymphomainfo.net/news/studies-and-trials/transplants-no-benefit-in-advanced-follicular-lymphoma
Cost-effectiveness of rituximab in follicular lymphoma.
In advanced follicular lymphoma, rituximab is currently used with chemotherapy as induction therapy, and as maintenance monotherapy following induction in previously untreated patients and treatment-experienced relapsed/refractory patients. Herein, thttp://www.biomedsearch.com/nih/Cost-effectiveness-rituximab-in-follicular/23140274.html